Bharat Biotech seeks EUA for Covaxin
No date has been fixed as on when the SEC will meet for assessing and evaluating the applications, as per sources
After Pfizer and Serum Institute, Bharat Biotech applied to the central drug regulator seeking emergency use authorisation for its COVID-19 vaccine Covaxin, official sources said.
Covaxin is being indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
The applications of Bharat Biotech, Serum Institute of India and Pfizer will be reviewed by the subject expert committee (SEC) on COVID-19 at the Central Drugs Standard Control Organisation (CDSCO) in the coming days.
“However, none of the applications has so far been forwarded to the committee and no date has been fixed as on when the SEC will meet for assessing and evaluating the applications,” the official source said.
(Edits by EP News Bureau)